What is Leerink Partnrs’ Forecast for STOK FY2025 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($1.50) per share for the year, up from their previous forecast of ($2.25). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($3.25) EPS and FY2028 earnings at ($2.95) EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Other research analysts also recently issued reports about the stock. Chardan Capital initiated coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partners began coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $10.99 on Friday. Stoke Therapeutics has a 1 year low of $4.09 and a 1 year high of $17.58. The stock has a 50-day moving average price of $11.08 and a 200 day moving average price of $12.72.

Insider Activity

In other news, insider Barry Ticho sold 2,586 shares of Stoke Therapeutics stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $33,592.14. Following the transaction, the insider now directly owns 44,746 shares in the company, valued at approximately $581,250.54. The trade was a 5.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,786 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total value of $88,150.14. Following the sale, the chief executive officer now owns 61,885 shares of the company’s stock, valued at approximately $803,886.15. The trade was a 9.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 over the last 90 days. 11.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in shares of Stoke Therapeutics by 528.6% during the 2nd quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock worth $3,905,000 after purchasing an additional 243,083 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after acquiring an additional 1,123,500 shares during the period. Mesirow Financial Investment Management Inc. acquired a new position in shares of Stoke Therapeutics in the third quarter valued at $192,000. Finally, Los Angeles Capital Management LLC lifted its position in Stoke Therapeutics by 54.3% in the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock worth $1,266,000 after purchasing an additional 36,240 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.